Research at Fox Chase »Technology Transfer »Technology Licensing

« Technology Licensing

Article from the Journal of Virology, Sept. 2003 [PDF]
(This link requires Adobe^® Acrobat Reader to view.)

Dr. Christoph Seeger and colleagues of Fox Chase Cancer Center have developed stable human non-hepatic cell lines and murine hepatic cell lines that express subgenomic HCV replicons. Replicons express NS3 protease and NS5B polymerase, key targets for anti-hepatitis C virus (HCV) drug development.

These are the first stable human non-hepatic cell lines and murine hepatic cell lines to express these proteins in the context of replicating the HCV genome.

Applications:	Independent validation of anti-HCV drug testing Enables researchers to determine how anti-HCV agents are metabolized or exhibit toxicity in different cell types Tools for the characterization of virus assembly and replication
Opportunity:	Fox Chase is seeking commercial partners who are active in the development of anti-HCV therapeutics for licensing and collaboration.
Patent status:	A U.S. patent application has been filed that covers the cell lines and methods for generating new HCV-expressing cell lines.
Publication:	Zhu Q et al., "Replication of Hepatitis C Virus Subgenomes in Nonhepatic Epithelial and Mouse Hepatoma Cells," Sept 2003. J. Virology 77: 9204-9210.
Contact:	Clarissa Ceruti, PhD, MBA Associate Director Business Development clarissa.ceruti@fccc.edu Phone 215 214-1546